Parties will identify unique miRNA biomarkers that also have prognostic potential.
Rosetta Genomics and Henry Ford Health System in Detroit, MI, will work together to develop miRNA-based diagnostics and prognostics for brain cancer. The parties will jointly conduct a genome-wide molecular analysis of human brain cancer tumors to identify unique miRNA biomarkers that have diagnostic and prognostic potential.
Upon receipt of the results from this analysis, Rosetta Genomics will use its miRNA extraction technologies to perform an analysis from FFPE samples received from Henry Ford Hospital.“A significant advantage of using microRNAs as biomarkers, is that they do not degrade when the tumor sample is stored as an FFPE block,” notes Chaya Brodie, Ph.D., director of the William and Karen Davidson laboratory of cell signaling at Henry Ford Hospital.
“As FFPE blocks can be stored at room temperature, these sample types are readily available and allow us to conduct retrospective studies. Through these studies, we can identify microRNA diagnostic and prognostic biomarkers such as for disease staging, response to treatment, and risk of recurrence.”